[Microdialysis cerebral. Main application of this technique].
BACKGROUND
Microdialysis cerebral technique has been widely employed in order to study the neurotransmitter release.


METHODS
This technique present numerous advantages such as: allow to work with sample in vivo from animals freely moving, by means of microdialysis can be infused simultaneously different drugs in different points implanted probes in several coordinates; also allow carry out pharmacokinetics studies that show correlation with behavior patter as well as to study metabolic changes, which is not possible when this determination are carry out in tissue, in post mortem stadio.


CONCLUSIONS
In the present work is carry out a review about the main results obtaining in the sensitization and abstinence to several drug study and approach to biochemical characteristics to Parkinson s disease (PD) by means of microdialysis technique. In relation to sensibilization studies, the temporal changes in different behavior pattern that modify after amphetamine administration have been studied. Microdialysis study allowed correlationate dopamine concentration with behavior pattern above mentioned. In relation with PD, dopamine concentration after systemic and central (intracerebral) administration of levodopa and another dopaminergic drugs have been studied in different nucleus of basal ganglia as well as its respectively behavior correlates.
Blanco-Lezcano
L
L
Grupo de Trastornos del Movimiento y Enfermedad de Parkinson. Area Básica. Centro Internacional de Restauración Neurológica (CIREN), Ciudad de La Habana, Cuba. lisette@neubas.sld.cu
Pavón-Fuentes
N
N
Blanco-Lezcano
V
V
D000661:Amphetamine / Q000008:administration & dosage / Q000493:pharmacokinetics; D000818:Animals; D000978:Antiparkinson Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D001479:Basal Ganglia / Q000378:metabolism; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000378:metabolism*; D003342:Corpus Striatum / Q000378:metabolism; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism*; D007980:Levodopa / Q000493:pharmacokinetics / Q000627:therapeutic use; D017551:Microdialysis / Q000379:methods*; D009714:Nucleus Accumbens / Q000378:metabolism; D010300:Parkinson Disease / Q000188:drug therapy / Q000378:metabolism*; D051381:Rats; D011954:Receptors, Dopamine / Q000378:metabolism
D000978:Antiparkinson Agents; D011954:Receptors, Dopamine; D007980:Levodopa; D000661:Amphetamine; D004298:Dopamine